Discovery US
Join and network with over 250 industry leaders at Discovery US 2023, where we will address the latest advancements in target identification, validation and HIT optimisation.
Join and network with over 250 industry leaders at Discovery US 2023, where we will address the latest advancements in target identification, validation and HIT optimisation.
Listen to our talk and meet our team!
Come and visit our team at our stand #1 to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.
Timothy Smith, Associate Director of Sales - North America, will be our speaker and his talk will be on "Building Robust Pre-Clinical Drug Discovery Workflows with Precision Reprogrammed Human iPSC-derived Cells" on Day 2 track "Animal models for disease, organ modelling - organoid based discovery & organ on chip development" at 9:50am.
In this talk he will cover:
- Address the challenges of implementing hiPSC-derived cells in the drug discovery process from Target ID/Validation through to candidate selection
- Learn how a new technology is overcoming inconsistencies in human cell production to enable the generation of highly defined, rapidly maturing hiPSC-derived cells
- Discover success stories where precision reprogrammed hiPSC-derived cells have supported CRISPR screens to identify druggable targets for neurodegeneration and lead generation of antisense oligonucleotide therapeutics for genetic diseases.